Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by trade2win2on Apr 27, 2012 9:02am
171 Views
Post# 19842996

Agenda upcoming Meeting

Agenda upcoming Meeting

Someone a few post back called a possible " CONSOLIDATION OF SHARES" looks like you called it right...

Quetzal Energy Ltd. Announces Details of Upcoming Annual General and Special Meeting of Shareholders

ccnm

TORONTO, ONTARIO--(Marketwire - April 27, 2012) - Quetzal Energy Ltd. (TSX VENTURE:QEI) ("Quetzal" or the "Company") announces that an annual and special meeting (the "Meeting") of the holders ("Shareholders") of its common shares ("Common Shares") will be held at the offices of Torys LLP, Suite 3000, 79 Wellington Street West, TD Centre, Toronto, Ontario on Thursday, May 31, 2012, at 2:00 p.m. (Toronto time) for the following purposes:

to receive the financial statements of the Company, together with the report of the auditors thereon for the year ended December 31, 2011;

to fix the number of directors of the Company to be elected at the Meeting at 6;

to elect the directors of the Company for the ensuing year;

to consider, and if thought fit, pass a special resolution to authorize the board of directors of the Company (the "Board") to, between annual meetings of Shareholders, determine or fix the number of directors by resolution, within the minimum and maximum number provided for in the articles of the Company;

to appoint auditors of the Company for the ensuing year;

to consider, and if thought fit, pass a special resolution to amend the articles of the Company to change the name of the Company from "Quetzal Energy Ltd." to "Santa Maria Petroleum Inc." or such other name as the Board deems appropriate, in its sole discretion;

to consider, and if thought fit, pass a special resolution to approve the Company's new stock option plan;

to consider, and if thought fit, pass a special resolution to amend the articles of the Company to consolidate the issued and outstanding Common Shares on the basis of one post-consolidation Common Share for every 10 pre-consolidation Common Shares or such lesser ratio that the Board deems appropriate, in its sole discretion (the "Consolidation"); and

to transact such other business as may be properly brought before the Meeting or any adjournment thereof.

The specific details of the matters proposed to be put before the Meeting will be set forth in a proxy statement and information circular to be mailed to Shareholders and will be made available on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

The Board believes that consolidation of the Common Shares should enhance their marketability as an investment and should facilitate additional financings to fund operations in the future. The Consolidation is subject to TSX Venture Exchange (the "TSXV") approval. Subject to obtaining Shareholder and TSXV approval, the 600,764,492 pre-consolidation Common Shares that are currently outstanding would be reduced to approximately 60,076,449 post-consolidation Common Shares.

If the Consolidation is implemented, fractional post-consolidation Common Shares will not be issued to Sh

Bullboard Posts